Long regarded as a grim and unrelenting disease with generally poor prognosis and inadequate treatment options, 1 hypertrophic cardiomyopathy (HC) has now become a contemporary treatable disease with reasonable expectation for extended or normal longevity in many patients.
2e6 HC-related mortality has decreased significantly due principally to penetration of implantable cardioverter-defibrillators into disease management for prevention of sudden death (SD). 2 Patients with HC are, of course, still subjected to all-cause and noncardiac mortality because of a variety of other organ system diseases.
2e6
To determine the causes of mortality in a contemporary HC population, which may require redefinition in the rapidly evolving treatment environment for this complex genetic heart disease, 2À6 we studied natural history and outcome of 1,902 consecutive patients. These patients were evaluated between 1992 and 2013 (27% obstructive at rest with outflow gradient, !30 mm Hg) at 2 HC referral institutions: Minneapolis Heart Institute Foundation and Tufts Medical Center (Boston) with complete follow-up over 6.6 AE 5.3 years.
2À4
Of 1,902 patients, 1653 patients (87%) survived to the end of follow-up, whereas 249 patients (13%) have died ( Figure 1 ). Most deaths (n ¼ 178 of 249; 72%) were due to causes unrelated to HC, predominantly in patients aged !60 years: cancer (n ¼ 37), other noncardiac (n ¼ 16), coronary artery disease (n ¼ 15), postoperative, including surgical myectomy (n ¼ 9), advanced age associated with multiple cardiovascular and other organ system involvement, and co-morbidities largely independent of HC (n ¼ 71; including nursing home deaths in patients aged >90 years [n ¼ 20]; lost to follow-up [n ¼ 10]).
The other 71 of the 249 deaths (28%) were due to causes directly related to HC: SD (n ¼ 31); heart failure (n ¼ 17); embolic stroke (n ¼ 8); postoperative (n ¼ 7); and transplant complications (n ¼ 8). Notably, deaths due to non-HC causes substantially exceeded HC-related causes by 2.6-fold (p <0.001; Table 1 ).
When mortality was analyzed with respect to age at presentation, distinct differences were evident (Table 1) . Non-HC mortality was most common in adults presenting !60 years and least common in youngest patients aged <30 years (p <0.001). For HC deaths, an inverse relation was present with mortality greatest in the youngest patients and least common in older patients (p <0.001). Patients with non-HC death were significantly older than patients with HC-related mortality (74 AE 14 vs 48 AE 18 years; p <0.001).
A new diagnosis of HC represents a landmark for many patients, usually unprepared for a disease often presented in the context of potentially profound clinical consequences, (particularly SD). 6 Indeed, a HC diagnosis often dominates the patient perception of their overall clinical profile, even in the presence of other non-HC conditions with more profound implications. Therefore, we find many patients come to believe that with aging, HC will become a relentlessly progressive disease process ultimately leading to their demise. The present data, however, clearly dispute such patient intuitions by showing that risk for death in adult patients with HC is significantly greater due to diseases other than HC. Indeed, it is very possible for adult patients in low HCrelated risk groups to become distracted by HC and neglect preventive measures for other potentially lethal conditions such as cancer or coronary artery disease. In contrast, not unexpectedly, in children, adolescents, and young adults aged <30 years with HC, mortality is predominantly due to HC, given that deaths from other disorders are rare in this age group.
All-cause mortality in HC exceeds that in the general population 4e6 likely because deaths due to HC are part of the calculated total mortality. However, adverse interaction between HC and other disease processes that potentially increase lifetime risk cannot be absolutely excluded.
An important message often lost to patients with HC is that their disease is not ultimately lethal, but rather consistent with extended (if not normal) longevity, given that adverse clinical consequences and complications can now be anticipated and accompanied by effective treatment options. 1,4e6 In conclusion, although HC has been cited as a highly visible cause of SD in the young, paradoxically it is uncommonly responsible for mortality in established HC patient cohorts. Only about 25% of patients with HC ultimately die of their disease, and indeed, mortality in adult patients with HC is more frequently due to other organ system diseases. These insights empower many patients to adopt a more realistic and reassured perception of their disease and promote the importance of surveillance and preventive strategies for non-HC conditions which may harbor greater potential for morbidity and mortality.
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